Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Dec 01, 11:46AM CST
ANV: 0.74 (-0.04), FRO: 2.25 (+0.62), EXXI: 2.84 (unch), SPRO: 1.72 (+0.01), EMES: 44.67 (+0.92), BDR: 2.28 (-0.02), SPHS: 2.82 (+0.03), ISR: 1.62 (-0.02), MILL: 1.24 (unch), EOX: 0.97 (-0.31), NADL: 1.47 (-0.09), ORPN: 6.71 (-0.54), CANF: 3.49 (+0.03), LAS: 0.98 (-0.09), MOLG: 2.90 (-0.05), PSIX: 44.36 (-1.35), GDP: 3.93 (-0.33), LRE: 7.47 (-0.06), NGD: 4.35 (+0.04), BDL: 32.60 (+0.30)
Sophiris Bio to Present at the 26th Annual Piper Jaffray Healthcare Conference
Business Wire - Tue Nov 25, 7:00AM CST
Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"
SPHS: 2.82 (+0.03)
Sophiris Bio - Upcoming Catalysts Present Very Attractive Upside
Daniel Ward - at Seeking Alpha - Mon Nov 24, 8:30AM CST
SPHS: 2.82 (+0.03)
Sophiris Bio beats by $0.03
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 3:55PM CST
SPHS: 2.82 (+0.03)
Sophiris Bio Reports Third Quarter Financial Results
Business Wire - Wed Nov 12, 3:05PM CST
Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"
SPHS: 2.82 (+0.03)
Sophiris Bio to Present at the Stifel 2014 Healthcare Conference
Business Wire - Fri Nov 07, 3:05PM CST
Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"
SPHS: 2.82 (+0.03)
Strength Seen in Sophiris Bio (SPHS): Stock Soars 25% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 8:46AM CST
Sophiris Bio (SPHS) was a big mover last session, as the company saw its shares surge 25% on the day.
ICUI: 80.95 (-1.04), ABAX: 57.20 (+0.61), GWPH: 72.41 (+1.18), SPHS: 2.82 (+0.03)
3 Under-$10 Health Care Stocks Triggering Breakout Trades
at The Street - Fri Oct 10, 8:08AM CDT
Keep these health care stocks under $10 on your breakout trading radar.
SPHS: 2.82 (+0.03), PIP: 1.72 (+0.01), MEIP: 4.20 (unch)
Sophiris Bio to Present at the 13th Annual BIO Investor Forum
Business Wire - Tue Sep 30, 7:01AM CDT
Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"
SPHS: 2.82 (+0.03)
Sophiris Bio Reports Completion of Enrollment in the "PLUS-1" Phase 3 Trial of PRX302 for Benign Prostatic Hyperplasia
Business Wire - Tue Sep 02, 7:00AM CDT
Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"
SPHS: 2.82 (+0.03)
Sophiris Bio Reports Second Quarter Financial Results and Key Operational and Financial Highlights
Business Wire - Thu Aug 07, 3:06PM CDT
Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"
SPHS: 2.82 (+0.03)